BC3402
Phase 2Small molecule
BC3402 is one of 30 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
265 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Ibrance
PfizerPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Hepsera
GileadPreclinical
Doptelet
AAkarx
Preclinical
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Preclinical
Vermox
WWim Janssens
Preclinical
BC3402
BBiocity Biopharmaceutics Co., Ltd.
Phase 2
Valemetostat
Bristol-Myers SquibbPreclinical
Alcohol
AstellasPreclinical
Chemotherapy Drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BC3402. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details